Y-mAbs Therapeutics Announces U.S. FDA Clearance Of Investigational New Drug Application For CD38-SADA
Portfolio Pulse from Benzinga Newsdesk
Y-mAbs Therapeutics has announced that the U.S. FDA has cleared its Investigational New Drug (IND) application for CD38-SADA. This clearance allows the company to proceed with clinical trials.
October 17, 2023 | 8:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Y-mAbs Therapeutics' stock may see positive movement as the FDA clearance for its IND application for CD38-SADA allows it to proceed with clinical trials.
The FDA clearance of the IND application for CD38-SADA is a significant milestone for Y-mAbs Therapeutics. This allows the company to proceed with clinical trials, which could potentially lead to the development of a new drug. This positive news could increase investor confidence in the company, leading to a potential increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100